The proposed transaction offers Lantheus shareholders $102.50 in cash upfront, with an additional $12.00 per share tied to non-transferable Contingent Value Rights. These payouts depend on hitting specific commercial sales milestones for prostate cancer diagnostics, neurology diagnostics, and the DEFINITY product line through 2030. Ademi LLP is currently examining whether these terms, combined with restrictive "no-shop" clauses that penalize competing bids, constitute a breach of fiduciary duty.
Ademi LLP Scrutinizes Lantheus Holdings Over Curium Acquisition Deal
A potential $114.50 per share valuation for Lantheus Holdings has triggered a legal inquiry from Ademi LLP. The investigation centers on whether the board of directors prioritized insider benefits over the interests of public shareholders during the firm's acquisition agreement with Curium, potentially undervaluing the company’s long-term market position.
Legal counsel suggests the deal structure unfairly favors insiders through change-of-control arrangements while limiting the board's ability to seek superior offers. The investigation seeks to determine if the current agreement maximizes value for all stakeholders or if the board failed to conduct a sufficiently robust sale process.
Comments (0)
No comments yet. Be the first!